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ARTICLE
Phase 1 Studies of Acebilustat: Biomarker Response and
Safety in Patients with Cystic Fibrosis
JS Elborn1, A Horsley2, G MacGregor3, D Bilton4, R Grosswald5, S Ahuja5 and EB Springman5,∗
There is a significant unmet need for safe and effective anti-inflammatory treatment for cystic fibrosis. The aim of this study
was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in
patients with cystic fibrosis. Seventeen patients with mild to moderate cystic fibrosis were enrolled and randomized into groups
receiving placebo or doses of 50 mg or 100 mg acebilustat administered orally, once daily for 15 days. Sputum neutrophil counts
were reduced by 65% over baseline values in patients treated with 100 mg acebilustat. A modestly significant 58% reduction
vs. placebo in sputum elastase was observed with acebilustat treatment. Favorable trends were observed for reduction of
serum C-reactive protein and sputum neutrophil DNA in acebilustat-treated patients. No changes in pulmonary function were
observed. Acebilustat was safe and well tolerated. The results of this study support further clinical development of acebilustat
for treatment of cystic fibrosis.
Clin Transl Sci (2016) 00, 1–7; doi:10.1111/cts.12428; published online on 0 xxxx 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Persistent neutrophilic lung inflammation is a major
cause of morbidity and mortality in CF. Safe and effective
anti-inflammatory treatment remains a significant unmet
need. Acebilustat is a potential new anti-inflammatory treat-
ment intended to target the excessive influx of neutrophils
into the lungs of patients with CF.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Whether once-daily oral acebilustat is tolerable and
safe for further testing and whether it shows initial signs
of pharmacologic or therapeutic effect in patients with CF.
We address these questions by evaluating adverse events,
lung function, and biomarkers related to inflammation and
infection.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ We found that once-daily oral acebilustat showed
promising trends in the reduction of both sputum and blood
biomarkers related to inflammation without changing sys-
temic or respiratory markers of infection. No change in lung
function was observed. These results indicate that once-
daily oral acebilustat is well tolerated, safe for further devel-
opment, and may reduce both lung and systemic inflam-
mation in patients with CF. A longer clinical trial may be
required to observe changes in lung function.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ These findings support further clinical development of
once-daily oral acebilustat as a new treatment with poten-
tial to address lung inflammation in patients with CF.
Persistent lung inflammation remains the major cause of
morbidity and mortality for patients with cystic fibrosis (CF),
and is characterized by excessive neutrophil influx into the
airways that leads to tissue injury. The key mediators of
neutrophilic insult in CF lungs include DNA and elastase.
DNA expelled from neutrophils is a significant contributor
to mucus thickening and airway obstruction.1,2 Neutrophil-
derived elastase promotes lung tissue degradation and is
strongly correlated with progressive lung function decline
as well as acute pulmonary exacerbation.3–7 Elastase has
1Centre for Infection and Immunity, Dentistry, and Biomedical Sciences, Queens University School of Medicine, Belfast, UK; 2Centre for Respiratory Medicine
and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester, UK; 3West of Scotland CF Centre, Gartnavel General Hospital, Glas-
gow, UK; 4Department of Respiratory Medicine, Royal Brompton Hospital, London, UK; 5Celtaxsys, Inc., Atlanta, Georgia, USA. ∗Correspondence: EB Springman
(espringman@celtaxsys.com)
Companion Article: Phase 1 Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction
Received 2 September 2016; accepted 22 September 2016; published online on 0 xxxx 2016. doi:10.1111/cts.12428
also been shown to contribute to CF lung disease through
a number of other mechanisms, including inactivation of the
CF transmembrane conductance regulator and activation of
the epithelial Na+ channel, both of which exacerbate the
defective ion transport conditions underlying CF.8,9 Paradox-
ically, excessive elastase released by neutrophils in CF air-
ways also impairs host response to bacterial infection by
inactivating many proteins important for host defense.10,11
Development of direct elastase inhibitors that are effective
in humans has so far been elusive, perhaps because of the
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extraordinarily high local concentrations of elastase at the
neutrophil surface.12
A logical approach to treating CF lung inflammation is
to reduce the excessive migration of neutrophils into the
lungs, thereby reducing release of both neutrophil-derived
DNA and elastase in the airways. Identifying the primary
drivers of neutrophil influx and activation in the CF lung is
the subject of much current research.13,14 One such candi-
date is leukotriene B4 (LTB4), a potent lipid mediator of neu-
trophil migration and activation.15 LTB4 is produced by the
action of the enzyme leukotriene A4 hydrolase (LTA4H) on
the intermediate arachidonic acid product leukotriene A4.15
LTB4 has recently been identified as a requisite mediator of
neutrophil swarming behavior and serves as a neutrophil-to-
neutrophil relay signal in order to amplify an initial inciting
inflammatory signal, such as formyl peptides.16,17 LTB4 sig-
naling from neutrophils also initiates a cascade of cytokines
and chemokines that further amplify and sustain inflamma-
tion as well as perpetuate further neutrophil recruitment.18,19
Furthermore, LTB4 has been shown to stimulate neutrophils
to release elastase, and conversely elastase can stimulate
accumulation of LTB4.20,21 Consistent with these findings,
generation of LTB4 is increased in the lungs of patients with
CF and correlates with disease severity.22,23 Taken together,
these findings suggest that, once incited, neutrophils may
form a self-sustaining inflammatory cycle of LTB4 genera-
tion and neutrophil recruitment that results in persistent and
excessive release of neutrophilic DNA and elastase into the
airways of patients with CF. Breaking this cycle by intervening
in the production of LTB4 is an attractive target for treatment
of CF airway inflammation.
We hypothesized that reducing LTB4 production via selec-
tive inhibition of LTA4H would provide measurable and
potentially beneficial anti-inflammatory effects. Acebilustat
(CTX-4430) is a direct and selective inhibitor of LTA4H in
development as a once-daily oral anti-inflammatory treat-
ment for CF. Pharmacokinetics and pharmacodynamics of
acebilustat in healthy volunteers and patients with CF,
reported separately, indicate that 50 mg and 100 mg once-
daily oral doses of acebilustat significantly reduce LTB4 pro-
duction, and, thus, are potentially effective doses for anti-
inflammatory treatment of CF. Here, we report the results for
biomarkers and safety from a first-in-human phase I clinical
study in patients with CF treated for 15 days with 50 mg
or 100 mg once-daily oral acebilustat or matched placebo.
The aim of this study was to assess tolerability and safety as
well as to generate initial data on potential anti-inflammatory
effects of acebilustat using a range of biomarkers related to
inflammation, infection, and immune system status.
METHODS
Study design
This study was carried out using a randomized, double-
blind, placebo-controlled dose escalation design, with study
treatment administered orally once daily for 15 days.24
Adult male and female patients with CF aged 18–55 years
and having percent predicted forced expiratory volume 1
(FEV1)  50% and  90% as well as body mass index of
least 17.0 Kg/m2 were eligible to participate in this study.
Assessments were performed on day -1 (1 day before the first
Figure 1 Study timeline and biomarker data collection points.
Black shaded areas with white text indicate biomarker test points
used for analysis in relation to treatment period. BSL, baseline; SS,
steady state; EOT, end of treatment; INT, interim.
dose of study treatment) to study day 2 (day after first study
treatment), on study days 7–9 for interim evaluation, on study
days 14–16 (day after last study treatment) for end of treat-
ment evaluation, and for follow-up on day 22, as shown in
Figure 1. The protocol and informed consent documents
were reviewed by the Office for Research Ethics Committees
Northern Ireland and all patients provided informed consent.
Two study cohorts were enrolled with a planned cohort
size of nine, consisting of three placebo-treated and six
acebilustat-treated patients. In the first cohort, nine patients
were randomized to receive either 50 mg acebilustat or
matching placebo capsule. After an escalation review of
the safety data from the first cohort, a second cohort was
enrolled and patients were randomized to receive either
100 mg acebilustat or matching placebo capsule. Due to
lack of additional available patients, the second cohort was
stopped at a total enrollment of eight patients. For all anal-
yses, the placebo-treated patients from each dosing cohort
were combined as a unified group called “placebo.”
Study procedures
Induced sputum samples were collected on study days -1
(baseline), 2 (day after first dose), 9 (acebilustat steady state),
16 (day after last dose), and 22 (follow-up), as shown in
Figure 1. Sputum induction was performed at the clini-
cal sites based on previously described methods.25 Speci-
mens were collected and processed at the clinical sites and
split into two subsamples after gentle mechanical homog-
enization. One subsample was immediately processed for
cell counting and bacterial culture, and the other subsam-
ple was further processed and preserved for soluble and
cellular markers, including neutrophil elastase and DNA.26,27
Lung clearance index was performed on study days -1 (base-
line), 7, and 16 (end of treatment) using the SF6 multi-
ple breath washout method, as previously described.28 Raw
data from multiple breath washout tests were read centrally
by a single observer blinded to treatment, as per recent
recommendations.29
Statistical analysis
For the analysis of total white blood cell (WBC) counts, neu-
trophil counts, elastase, and DNA in sputum, specimens
taken after the end of treatment (day after final treatment)
were compared with specimens taken at baseline (day prior
to first treatment). These data are presented as percent-
age change from baseline for each individual patient, then
compared as the combined group of all patients receiving
acebilustat (treated, including both the 50 mg and 100 mg
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dose groups) vs. placebo and also by individual treatment
groups (placebo, 50 mg acebilustat, and 100 mg acebilus-
tat). Samples for sputum microbiology were examined from
study days -1 (baseline), 2 (day after first dose), 9 (interim),
16 (end of treatment), and 22 (follow-up), and analyzed longi-
tudinally or by comparing colony-forming units (CFUs) at the
end of treatment (day after final treatment) to baseline (day
before first treatment).
Two systemic markers of inflammation were studied;
serum C-reactive protein (CRP) and circulating neutrophil
count. Blood samples collected on study day 14 (day before
final treatment) were compared with specimens taken at
baseline (day prior to first treatment). Treatment was stopped
early for one patient in the placebo group due to increased
CRP on study day 8. Therefore, this placebo patient is omit-
ted from all analyses other than safety, yielding a placebo
group of four.
Statistical comparison of the full treated group to placebo
was carried out using an unpaired parametric one-tailed
t-test with 95% confidence level. For statistical compari-
son of the acebilustat dose groups to placebo, a one-way
analysis of variance was carried out using Dunnett’s multi-
ple comparison test with a 90% confidence level. For results
with at least modest statistical significance (P = 0.05; 95%
confidence), the P value is reported in the results and fig-
ures. Nonsignificant values are reported as “ns”. Data for
all analyses included in this study were graphed and statis-
tical analyses were performed using GraphPad Prism ver-
sion 5.00 for Windows (GraphPad Software, La Jolla, CA;
www.graphpad.com).
RESULTS
A total of 17 patients with CF entered the study and were
randomized to study treatment. Of the 17 patients partici-
pating in the study, 4 were female and 13 were male. The
study patients ranged in age from 21–39 years old, in body
weight from 51.0–98.3 kg, and in body mass index from
19.60–27.90 kg/m2. A total of 16 patients completed the
study. One patient in the placebo group discontinued par-
ticipation in the study prior to dosing on day 8 due to an
adverse event of elevated serum CRP. Therefore, this patient
was excluded from the analyses other than safety, resulting in
a placebo group size of four. Hematology measures were not
taken for one patient in the 100 mg acebilustat dose group
on day 14, therefore, this patient is excluded from the analy-
sis of peripheral blood neutrophils resulting in a 100 mg dose
group of 5 and a combined treated group size of 11 for analy-
sis of peripheral blood neutrophil count. In some cases, such
as for sputum WBC and neutrophil cell counts, data for spe-
cific samples were missing or not obtainable and the group
size reflects the lack of analyzable data for these samples.
Inflammation biomarkers
Decreases were observed in all sputum inflammation
biomarkers for the acebilustat-treated patients compared
with their own baselines and to the placebo group.
Notably, large dose-dependent reductions from baseline
were observed in sputum WBC and neutrophil counts in
the acebilustat-treated patients, as shown in Figure 2. For
Figure 2 Sputum white blood cell (WBC) and neutrophils counts
at end of treatment. Sputum WBC (top) and neutrophil (bottom)
counts taken at end of treatment (study day 16). Results are
expressed as percentage of baseline value (bsln; mean ± SD) for
each individual patient (shown as markers in the graphs). Analysis
was performed in two ways: combined acebilustat-treated group
(50mg and 100mg) vs. placebo (left), and as separate dose groups
placebo, 50 mg and 100 mg acebilustat (right).
sputum WBC, there was a 31% reduction from baseline in
the acebilustat-treated group (n = 11) and a 60% reduc-
tion from baseline in the 100 mg acebilustat group (range,
12–100% reduction; n = 5). Additionally, four of six patients
in the 50 mg acebilustat group and four of five patients in
the 100 mg acebilustat group showed reductions from their
own baseline in sputumWBC count. For sputum neutrophils,
there was a 34% reduction from baseline in the acebilustat
treated group (n = 11) and a 65% reduction from baseline
in the 100 mg acebilustat group (range, 23–100% reduction;
n = 5). Four of the five analyzable patients treated with 100
mg acebilustat showed reductions of at least 48% in sputum
neutrophils. In contrast, placebo-treated patients showed an
overall increase from baseline on both sputum WBC (62%
increase from baseline; n = 4) and neutrophils (56% increase
from baseline; n = 4).
Positive treatment trends were also observed for sputum
DNA and sputum elastase in this study (Figure 3), with a sub-
stantial proportion of treated subjects showing a decrease
from baseline and compared with placebo. There was amod-
estly significant 58% reduction in elastase in the treated
group compared with placebo (P < 0.05, one-tailed t-test).
There was no clear dose dependence for either marker; how-
ever, there was a trend toward proportions of patients show-
ing reductions with higher acebilustat doses.
There was an overall increase from baseline CRP of+2.7±
5.3 mg/L (mean± SD, n = 4) in patients treated with placebo,
whereas for the acebilustat-treated patients there was an
overall decrease from baseline CRP of -1.2 ± 6.2 mg/L
(n = 12). This difference was not statistically significant and
there was no clear dose dependence. Circulating neutrophil
counts did not change frombaseline (7.4± 3.1; n= 11) to end
of treatment (7.0 ± 3.1; n = 11) within the acebilustat-treated
www.wileyonlinelibrary/cts
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Figure 3 Sputum DNA and elastase at end of treatment. Sputum
DNA (top) and elastase (bottom) measures taken at end of treat-
ment (study day 16). Results are expressed as percentage of base-
line value (mean ± SD) for each individual patient (shown as mark-
ers in the graphs). Analysis was performed in two ways: combined
acebilustat-treated group (50 mg and 100 mg) vs. placebo (left),
and as separate dose groups placebo, 50 mg and 100 mg ace-
bilustat (right).
group. At the end of treatment, the acebilustat-treated group
was also not different from the placebo group (6.3 ± 3.3;
n = 4).
Sputum microbiology
Treatment with 50 or 100 mg acebilustat for 15 days did not
elicit a discernable pattern of change from baseline or a dif-
ference in pattern from placebo in the longitudinal data for
either total bacterial load or total observed genera, as shown
in Figure 4. Change from baseline CFUs in the treated and
placebo groups was examined by comparing samples from
end of treatment (day after last dose) to baseline (day before
first dose) and the results are depicted in Figure 5. No dif-
ference from baseline to end of treatment in total bacterial
CFU in the acebilustat-treated groups or vs. placebo was
observed. Apparent reduction in themean total bacterial load
in the acebilustat-treated group compared with the placebo
group are largely driven by one particularly large increase in
the placebo group and are not thought to reflect a reduction
in total bacterial load with acebilustat treatment.
Overall, six genera were observed across all treatment
groups: pseudomonas, hemophilus, staphylococcus, strep-
tococcus, Rothia, and Burkholderia. Two additional genera
were observed sporadically and only in the group treatedwith
100 mg acebilustat: actinomyces and lactobacillus. There
was no increase or decrease in presence or quantity of any
genera during 15 days of treatment with placebo or 50 or
100 mg/day acebilustat.
Lung function
No clear changes in percent predicted FEV1, forced vital
capacity, FEV25-75, or lung clearance index were observed
Figure 4 Longitudinal measures of bacterial colony-forming unit
(CFU) (left) and number of bacterial genera (right) for individual
patients (represented by different markers in the graphs) receiving
placebo (top), 50 mg acebilustat (middle) and 100 mg acebilustat
(bottom).
Figure 5 Sputum bacterial colony-forming unit (CFU) at end of
treatment. Sputum bacterial CFU counts taken at end of treatment
(study day 16). Results are expressed as percentage of baseline
value (mean ± SD) for each individual patient (shown as mark-
ers in the graphs). Analysis was performed in two ways: combined
acebilustat-treated group (50 mg and 100 mg) vs. placebo (left),
and as separate dose groups placebo, 50 mg and 100 mg ace-
bilustat (right).
between baseline and end of treatment with 50 or 100 mg
acebilustat, as shown in Figure 6.
Safety
Acebilustat was well tolerated in this study. Overall, 45
adverse events were reported for 14 of 17 patients in this
study: five of six patients treated with 50 mg acebilustat, six
of six patients treated with 100 mg acebilustat, and three of
five patients treated with placebo. A summary of safety data
is presented in Table 1. The most common treatment emer-
gent adverse events were headache, oropharyngeal pain,
abdominal pain, cough, increased sputum, and hemopty-
sis. These adverse events were mild or moderate in severity
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Figure 6 Lung function assessments at end of treatment. Percent
predicted forced expiratory volume (FEV)1 (top) and lung clear-
ance index (bottom) values taken at end of treatment (study days
15 and 14, respectively). Results are expressed as percentage of
baseline value (mean ± SD) for each individual patient (shown as
markers in the graphs). Analysis was performed in two ways: com-
bined acebilustat-treated group (50 mg and 100 mg) vs. placebo
(left), and as separate dose groups placebo, 50 mg and 100 mg
acebilustat (right).
Table 1 Summary of treatment emergent adverse events
Treatment
Event Placebo 50 mg 100 mg Overall
No. of patients starting treatment 5 6 6 17
No. of patients completing treatment 4 6 6 16
No. of patients with adverse event 3 5 6 14
Total no. of adverse events 7 14 24 45
Adverse events of mild severity 5 8 21 34
Adverse events with moderate severity 2 6 3 11
SAEs 0 1a 0 1
Discontinued due to adverse event 1 0 0 1
SAEs, serious adverse events.
aOccurred 29 days after last study treatment and discovered on extended
follow-up for pregnancy testing.
and were considered unrelated or unlikely to be related to
acebilustat. There were no serious adverse events related to
acebilustat. One serious adverse event of acute pulmonary
exacerbation of CF was reported in a subject who received
acebilustat 50 mg. However, the symptoms started about 4
weeks after receiving the last dose of acebilustat. Therefore,
this serious adverse event was assessed by the clinical site
investigator as being unlikely related to the investigational
product.
DISCUSSION
The biomarker results suggest that acebilustat is pharma-
cologically active at the exposures achieved with once daily
oral doses of 50 mg and 100 mg, and this is consistent with
the pharmacokinetic and pharmacodynamic profile reported
separately. Treatment of patients with CF with acebilustat
for 15 days resulted in apparent reductions in lung and sys-
temic markers of inflammation without adversely affecting
pulmonary infection status. For all inflammatory biomarkers
examined in blood (CRP) and sputum (WBC, neutrophils,
DNA, and elastase), acebilustat treatment showed a reduc-
tion compared with placebo. Reductions from baseline val-
ues were observed for sputum measures of WBC, neu-
trophils, DNA, and elastase. Additionally, dose-dependent
trends either in mean values of reduction from baseline (spu-
tum WBC and neutrophils) or in number of patients showing
a reduction from baseline (sputum DNA and elastase) pro-
vide additional evidence for an anti-inflammatory effect in the
lungs of patients with CF treated with once daily oral acebilu-
stat for 15 days.
Although not statistically significant, the reduction in serum
CRP in patients with CF treated with acebilustat when com-
pared with baseline (-1.2mg/L) or to placebo (-3.9mg/L) sug-
gests a potential systemic anti-inflammatory effect of ace-
bilustat treatment in patients with CF. This is notable because
serum CRP is strongly correlated with systemic inflamma-
tory status and risk for pulmonary exacerbations in CF.30–32
WBC and neutrophil counts in sputum provide an overall indi-
cation of lung inflammation status. Sputum DNA and elas-
tase are important markers of neutrophilic inflammation in
CF. Moreover, they are important active contributors to CF
lung disease. Neutrophil-derived DNA is a significant con-
tributor to mucus viscosity and airway obstruction.2,33 Elas-
tase is a key mediator of lung tissue degradation, bac-
terial clearance deficiency and ion transport dysfunction
that is highly correlated with lung disease and functional
decline.3,5,6,8,10,11
Recent reports have suggested that direct inhibition of
LTA4H in mice may lead to increased inflammation. This
effect is thought to result from decreased clearance of
the proinflammatory tripeptide proline-glycine-proline, which
is generated from breakdown of interstitial matrix pro-
teins and eliminated via hydrolysis at the Pro-Gly bond by
the aminopeptidase function of LTA4H.34 Although proline-
glycine-proline levels in the lung were not measured in
this study, it is worth noting that all acebilustat-treated
patients in this study were colonized with hemophilus and
most with pseudomonas, staphylococcus, and streptococ-
cus as well. In spite of the prevalent pulmonary coloniza-
tion status of the acebilustat-treated patients, there was
a consistent decrease in all measures of inflammation,
including decreases in sputum WBC and neutrophils with
correlated decreases in inflammatory neutrophil products
(DNA and elastase) and no signs of increased pulmonary
infection or systemic inflammation (CRP). The reason for the
difference in these outcomes remains to be determined, but
could potentially be explained by differences in the level
of inhibition of LTA4H aminopeptidase function in the lung,
as well as differences between human CF disease and ani-
mal model systems. Whatever the source of the disparity
in outcomes, the results of this study clearly demonstrate
that acebilustat treatment does not seem to increase lung
inflammation and, in contrast, provide strong evidence that
www.wileyonlinelibrary/cts
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acebilustat reduces lung and systemic inflammation in
patients with CF.
Previous attempts to intervene in LTB4 signaling and its
consequent neutrophilic inflammation in CF have met with
mixed outcomes. Konstan et al.35 and VanDevanter et al.36
showed that high-dose ibuprofen was able to reduce the
decline of lung function over time and to improve survival
in patients with CF. The likely mechanism of the high-dose
ibuprofen therapeutic effect in patients with CF has been
attributed to a secondary pharmacology of reducing LTB4
production based on nonclinical and clinical studies.37,38 In
contrast, a large phase II clinical trial of the LTB4 recep-
tor antagonist amelubant (BIIL-284) in patients with CF
showed an increase in acute pulmonary exacerbations, lead-
ing to early termination of the study and discontinuation
of the program.39 No cause for the increased pulmonary
exacerbations could be attributed from the clinical studies
of amelubant, however, in subsequent nonclinical studies,
the increase in pulmonary exacerbations was attributed to
increased infection with amelubant treatment.40 Whether this
effect is unique to LTB4 receptor blockade or resulted from
too great a level of pathway inhibition remains unknown,
however, pharmacodynamic data suggest that the dosages
and exposures of amelubant in the terminated phase II trial
were in excess of that required for complete inhibition of BLT
receptor signaling.41 Regardless of the origin of the increased
pulmonary exacerbations observed in the phase II study, the
experience with amelubant urges caution in development of
anti-inflammatory treatments for CF. In contrast, the clinical
experience with high-dose ibuprofen suggests that the effect
seen with amelubant is not a general feature of intervention
in LTB4 signaling.
Acebilustat was safe and well tolerated in this study.
Adverse events were generally characterized as mild to mod-
erate in severity and were characterized by the investigators
as unlikely or not related to the study drug. In addition to
the clinical safety assessments, circulating neutrophil counts
and sputum microbiology were monitored during the course
of the study. No treatment-related changes were observed
in these measures. For circulating neutrophils, there was
no difference from placebo or change from baseline for the
acebilustat-treated patients with CF. Conversely, the lack
of a trend toward increase in circulating neutrophil counts
after 15 days of acebilustat treatment suggests that ace-
bilustat is unlikely to increase circulating neutrophils, as was
observed for amelubant after 28 days of treatment.39 Spu-
tum microbiology did not show any longitudinal pattern of
increase in total bacterial load, individual genera, or total gen-
era in acebilustat-treated patients with CF. There was also no
increase in total bacterial load compared with placebo, and
no dose-dependent change from baseline was observed.
Together, these results provide further evidence that treat-
ment with 50 mg or 100 mg acebilustat is not generally
immunosuppressive and is not likely to increase susceptibil-
ity to pulmonary infection in patients with CF.
In spite of the encouraging reductions in markers of
lung inflammation observed in patients with CF in this
study, no change was observed for spirometry mea-
sures or lung clearance index with 15 days of acebilus-
tat treatment. Because clearance of preexisting neutrophilic
material is slow in patients with CF due to thickened mucus,
stifled ciliary beat, and dysfunctional lung clearance is exac-
erbated by neutrophilic DNA, sputum DNA and elastase
values can be expected to change more slowly than neu-
trophil counts.2,42 It is therefore likely that the trends toward
reduction in these important disease effectors observed in
this study will continue to accrue over time with continued
treatment. Consequently, an even slower change in clinical
outcomes, such as FEV1, is reasonably anticipated with
treatments that primarily act by reducing lung inflammation
in CF. This effect is in contrast to that observed for treat-
ments that improve CF transmembrane conductance regu-
lator function, such as oral ivacaftor, treatments that actively
degrade preexisting DNA, such as inhaled dornase alpha, or
treatments that reduce bacterial infection, such as inhaled
aztreonam, which act in a matter of days to weeks.43–45
However, the lack of effect on lung function measures in
trials of short duration, even in the presence of effects on
inflammatory biomarkers, is consistent with prior experience
for anti-inflammatory treatments in CF.46,47 Conversely, even
though high-dose ibuprofen has demonstrated meaningful
improvements in clinical outcomes in trials of long dura-
tion, it exhibited minimal effects on inflammatory biomark-
ers in the short term.48 Taken together, these findings indi-
cate that a longer treatment period is required to observe a
change in clinical outcomes for anti-inflammatory treatments
in CF.
In conclusion, treatment of patients with CF with 50 mg
or 100 mg oral acebilustat once daily for 15 days was
safe and well tolerated. Although no improvements in lung
function were observed in this study, acebilustat treat-
ment showed promising signs of reduced lung and sys-
temic inflammation without signs of increased lung infec-
tion or systemic immunosuppression. The results of this
study support further development of acebilustat as a new
once daily oral anti-inflammatory for treatment of CF. A
phase II study assessing clinical outcomes in patients with
CF after 48 weeks of acebilustat treatment is currently in
progress.49
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